Saturday 17 October 2026
Export GERN’s income statement to Excel — free account
Geron Corporation
GERN Healthcare Biotechnology
Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024. In the quarter to June 2026, revenue grew 17.2%, EPS was flat, free cash flow grew 41.8% and total debt was flat, each against the same quarter a year earlier.
1.17
0.06
−4.88%
Follow GERN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
2 | 2 | 4 | 1 | 3 | 2 | 2 | 4 | 3 | 3 |
P/S ratio |
54.98 | 270.61 | 165.58 | 562.21 | 1,706.02 | 286.94 | 1,533.36 | 5,152.66 | 29.70 | 4.79 |
Altman Z-Score |
15.07 | 13.99 | 6.86 | (4.64) | (1.83) | (6.38) | (7.13) | (1.65) | 0.18 | (2.24) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(3.78) | (8.87) | 11.40 | (15.05) | (8.03) | (16.29) | (24.74) | (10.86) | (6.31) | (6.02) |
Beneish M-Score |
(3.61) | (0.32) | (1.06) | (4.41) | (2.36) | 0.23 | (1.20) | (2.66) | 286.22 | (1.70) |
P/Operating CF |
(562.74) | (65.69) | (58.64) | (24.95) | (34.22) | (18.03) | (25.98) | (29.83) | (52.04) | (39.88) |
P/B ratio |
2.77 | 2.78 | 0.99 | 1.91 | 2.05 | 3.16 | 11.42 | 4.93 | 8.16 | 3.90 |
Price to Tangible BV |
2.77 | 2.78 | 0.99 | 1.91 | 2.05 | 3.16 | 11.42 | 4.93 | 8.16 | 3.90 |
EV/Sales |
36.30 | 181.45 | 12.15 | 264.30 | 1,027.29 | 191.21 | 1,328.74 | 4,085.70 | 26.87 | 3.87 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(12.18) | (9.40) | (0.62) | (2.77) | (3.90) | (2.79) | (6.22) | (5.77) | (9.46) | (6.41) |
EV/FCF |
(12.15) | (9.38) | (0.62) | (2.75) | (3.88) | (2.78) | (6.20) | (5.74) | (9.43) | (6.40) |
Quick Ratio |
14.69 | 14.64 | 21.82 | 4.99 | 6.38 | 4.08 | 2.30 | 3.11 | 5.07 | 3.58 |
Current Ratio |
14.76 | 14.73 | 21.99 | 5.03 | 6.46 | 4.11 | 2.35 | 3.16 | 5.56 | 4.66 |
Net Debt/EBITDA |
3.84 | 3.29 | 5.11 | 1.87 | 2.29 | 1.20 | 0.89 | 1.25 | 1.56 | 3.28 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.54% | 9.20% | 22.44% | 26.84% | 20.79% | 19.95% | 20.95% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.02 | 0.12 | 0.40 | 0.64 | 0.33 | 0.42 | 0.53 |
Asset Turnover |
0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.16 | 0.32 |
Operating CF/Net income |
0.62 | 0.74 | 0.78 | 0.64 | 0.88 | 0.82 | 0.90 | 0.91 | 1.25 | 1.33 |
Capex/Depreciation |
(0.06) | 0.00 | 0.02 | 0.55 | (0.21) | (0.07) | (0.35) | 0.09 | 0.06 | 0.01 |
Interest Coverage |
(26.06) | — | — | — | (101.20) | (30.48) | (20.13) | (23.33) | (9.39) | (2.10) |
| (22.33%) | (24.69%) | (19.19%) | (43.82%) | (43.70%) | (68.84%) | (137.49%) | (112.29%) | (66.09%) | (32.99%) | |
| (21.17%) | (23.21%) | (18.28%) | (39.08%) | (34.67%) | (46.75%) | (68.12%) | (62.99%) | (35.34%) | (14.34%) | |
ROIC |
(263.57%) | (206.77%) | (137.01%) | 0.00% | (122.54%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(27.24%) | (31.17%) | (17.04%) | (60.21%) | (44.59%) | (81.58%) | (135.99%) | (78.53%) | (43.21%) | (20.39%) |
Average Days of Receivables |
28.14 | 149.43 | 399.93 | 636.37 | 1,041.62 | 461.95 | 1,925.44 | 2,548.84 | 183.93 | 77.86 |
Research and Development Expense of Revenue |
292.88% | 1,035.96% | 1,260.04% | 11,320.00% | 20,350.99% | 6,154.13% | 16,026.51% | 52,762.03% | 134.74% | 38.85% |
Selling, General and Administrative Expense of Revenue |
304.46% | 1,810.99% | 1,754.88% | 4,541.96% | 10,149.41% | 2,129.58% | 7,320.13% | 29,170.89% | 189.28% | 86.61% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
136.34% | 783.47% | 615.29% | 1,336.30% | 2,758.89% | 586.58% | 1,386.74% | 8,166.24% | 40.68% | 14.55% |
Graham Net Nets |
0.32 | 0.31 | 0.90 | 0.43 | 0.32 | 0.22 | 0.08 | 0.16 | 0.08 | 0.20 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(8.45%) | (9.94%) | (15.00%) | (26.47%) | (16.98%) | (29.51%) | (15.00%) | (15.42%) | (7.63%) | (9.85%) |
Free Cash Flow Yield |
(5.43%) | (7.15%) | (11.92%) | (17.11%) | (15.54%) | (23.96%) | (13.99%) | (13.80%) | (9.59%) | (12.62%) |
Revenue per Share |
0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.28 |
Operating CF per Share |
(0.12) | (0.13) | (0.12) | (0.23) | (0.25) | (0.29) | (0.33) | (0.29) | (0.34) | (0.17) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.12) | (0.13) | (0.12) | (0.23) | (0.25) | (0.29) | (0.34) | (0.30) | (0.34) | (0.17) |
Cash per Share |
0.72 | 0.60 | 0.93 | 0.73 | 0.72 | 0.56 | 0.45 | 0.59 | 0.63 | 0.54 |
Shareholders Equity per Share |
0.77 | 0.65 | 1.01 | 0.71 | 0.78 | 0.39 | 0.21 | 0.43 | 0.43 | 0.34 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.77 | 0.65 | 1.01 | 0.71 | 0.78 | 0.39 | 0.21 | 0.43 | 0.43 | 0.34 |
Free Cash Flow |
(18.41) | (20.56) | (21.02) | (44.24) | (67.05) | (95.76) | (127.81) | (168.57) | (219.30) | (111.09) |
Working Capital |
108.24 | 89.45 | 158.51 | 113.45 | 168.92 | 141.69 | 103.55 | 233.28 | 402.69 | 408.73 |
Capital Expenditures |
(0.04) | — | (0.02) | (0.41) | (0.40) | (0.21) | (0.43) | (0.83) | (0.68) | (0.05) |
Net Current Asset Value |
108.24 | 89.45 | 158.51 | 111.25 | 140.08 | 87.59 | 69.67 | 195.22 | 177.53 | 175.60 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.90 | 1.59 | 0.15 | 0.72 | 3.50 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
3.79 | 3.74 | (15.42) | (1.84) | 2.94 | 4.77 | 1.55 | (7.67) | (8.83) | (5.26) |
Cash ROIC |
(7.75%) | (10.34%) | (6.16%) | (15.95%) | (15.50%) | (26.51%) | (42.01%) | (25.36%) | (27.17%) | (15.75%) |
Accounts Receivable Turnover |
7.33 | 2.34 | 1.33 | 0.47 | 0.33 | 1.12 | 0.24 | 0.10 | 3.81 | 4.71 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.10 | 0.00 | 0.17 | 0.48 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.06 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3,117.18 | 4,284.97 | 0.00 | 2,497.75 | 865.92 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | 11,250.49 | 8,972.00 |
Average Receivables |
0.84 | 0.46 | 0.80 | 0.99 | 0.76 | 1.24 | 2.45 | 2.40 | 20.23 | 39.01 |
Average Payables |
0.19 | 0.36 | 0.74 | 1.08 | 4.05 | 6.80 | 8.44 | 8.18 | 7.38 | 9.93 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 77.68 |
Average Assets |
139.50 | 120.28 | 147.80 | 175.40 | 218.12 | 248.38 | 208.30 | 292.33 | 493.93 | 582.16 |
Average Common Equity |
132.25 | 113.09 | 140.77 | 156.44 | 173.05 | 168.68 | 103.21 | 163.97 | 264.13 | 253.10 |
Columns are period end dates